E
AMPH icon

Ergoteles’s Amphastar Pharmaceuticals AMPH Stock Holding History

Ergoteles’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10,024
Closed -$376K – 1027
2023
Q1 		$376K Buy
+10,024
New +$329K 0.01% 834
2021
Q2 		– Sell
-15,543
Closed -$285K – 1472
2021
Q1 		$285K Buy
+15,543
New +$289K 0.01% 576

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ergoteles's AMPH Position: Q2 2023 in Review

Ergoteles sold out of Amphastar Pharmaceuticals (AMPH) in Q2 2023, closing a stake of 10,024 shares — an estimated $376K sold.

Ergoteles first reported a position in AMPH in Q1 2021 and held it in 2 quarters. The position peaked at $376K in Q1 2023. 245 funds tracked by Wall St. Rank hold AMPH as of Q2 2023.

  • Ergoteles reported no remaining Amphastar Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Ergoteles sold 10,024 Amphastar Pharmaceuticals shares in Q2 2023, an estimated $376K.
  • Ergoteles first reported a position in Amphastar Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • Ergoteles's Amphastar Pharmaceuticals position peaked at $376K in Q1 2023.
  • 245 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.